South Carolina Supreme Court Slashes $327 Million Risperdal Verdict in Half

Published on March 16, 2015 by Laurie Villanueva

Text-Size:A A A+

 

The South Carolina Supreme Court reduced a $327 million verdict that was originally delivered in a Risperdal lawsuit against Johnson & Johnson by more than half, citing a three-year cap on claims involving the company’s violation of an Unfair Trade Practices Act in the state, according to Bloomberg.com.

The decision was reached in February and will reduce the drug manufacturer’s payment by 58 percent, to $136 million. The may come as a surprise to the healthcare giant, who last year won two high court battles in Louisiana and Arkansas that convinced them to throw out $1.5 billion worth of damage awards against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals. “We have maintained from the outset that we did not violate South Carolina’s Unfair Trade Practices Act, and we are reviewing all of our legal options,” a spokesperson for the company said.

Philadelphia Jurors Award $2.5 Million to Plaintiff in Risperdal Lawsuit

A day earlier, jurors in the Philadelphia Court of Common Pleas returned the first verdict in a Risperdal gynecomastia lawsuit that blamed Johnson & Johnson and Janssen for the male breast growth complications sustained by a man who took it as a child. The plaintiff was awarded $2.5 million in injury-related damages that resulted from health issues that resulted from gynecomastia, a condition referring to male breast growth. According to Bloomberg, this is one of 3,000 Risperdal claims to involve female breasts that were allegedly developed by men and young boys who took the antipsychotic medication. Plaintiffs in these cases also allege that Johnson & Johnson and Janssen promoted its product to children before it was cleared for pediatric uses in 2006.

Risperdal is an antipsychotic medication approved to treat schizophrenia and bipolar disorder in adults and adolescents, as well as irritability in children with autism. Research suggests that the drug is also frequently prescribed for ADHD.

In 2012, Johnson & Johnson and Janssen agreed to settle federally-filed claims involving the medication for $2.5 billion. The U.S. Department of Justice reported at the time that the Risperdal settlement was one of the largest involving healthcare fraud in the history of Pennsylvania federal court.

Call a Risperdal Lawyer

If you or a man you love sustained Risperdal breasts as a child taking the antipsychotic, the time is now to file a claim against Johnson & Johnson and Janssen. Call us now at .